Neuropathic Pain Frequency in Neurology Outpatients: A Multicenter Study

Can Ebru BEKİRCAN-KURT, Berin İNAN, Onur BULUT, İhsan ŞENGÜN, Necdet KARLI, Nalan GÜNES, Burcu Gökcioğlu ÇOKAL, Selda KESKİN GÜLER, Tahir Kurtuluş YOLDAŞ, Duygu GÜNER ÖZCANYÜZ, Filiz KOÇ, Zeynep ÜNLÜTÜRK, Çağdaş ERDOĞAN, Burhanettin ULUDAĞ, Cavit BOZ, Melih TUTUNCU, Mehmet Ali AKALIN, Özden KAMİŞLI, Abdülcemal ÖZCAN, Pınar KAHRAMAN KOYTAĞ, Kayihan ULUÇ, Sevim ERDEM-ÖZDAMAR, Ersin TAN

1Hacettepe University, Department of Neurology, Ankara, Turkey
2Dokuz Eylül University, Department of Neurology, Izmir, Turkey
3Uludağ University, Department of Neurology, Bursa, Turkey
4Ankara Training Hospital, Department of Neurology, Ankara, Turkey
5Çukurova University, Department of Pediatric Neurology, Adana, Turkey
6Ankara University, Department of Neurology, Malatya, Turkey
7Pamukkale University, Department of Neurology, Denizli, Turkey
8Ege University, Department of Neurology, Izmir, Turkey
9Karadeniz Technical University, Department of Neurology, Trabzon, Turkey
10Istanbul University Cerrahpasa Medical Faculty, Department of Neurology, Istanbul, Turkey
11Inonu University Turgut Ozal Medical Center, Department of Neurology, Malatya, Turkey
12Marmara University, Department of Neurology, Istanbul, Turkey

ABSTRACT

Introduction: Neuropathic pain is common, but the frequency of misdiagnosis and irrational is high. The aim of this study is to estimate the prevalence of neuropathic pain in neurology outpatient clinics by using valid and reliable scales and review the treatments of patients.

Methods: The study was conducted for 3 months in eleven tertiary health care facilities. All outpatients were asked about neuropathic pain symptoms. Patients with previous neuropathic pain diagnosis or who have neuropathic pain symptoms were included and asked to fill painDETECT and doulour neuropathic en 4 questions (DN4) questionnaire. Patients whose DN4 score is higher than 3 and/or painDETECT score higher than 13 and/or who are on drugs for neuropathic pain were considered patients with neuropathic pain. The frequency of neuropathic pain was calculated and the treatments of patients with neuropathic pain were recorded.

Results: Neuropathic pain frequency was 2.7% (95% CI: 1.5–4.9). The most common cause was diabetic neuropathy. According to painDETECT, the mean overall pain intensity was 5.7±2.4, being lower among patients receiving treatment. Pharmacological neuropathic pain treatment was used by 72.8% of patients and the most common drug was pregabalin. However, 70% of those receiving gabapentinoids were using ineffective doses. Besides, 4.6% of the patients were on medications which are not listed in neuropathic pain treatment guidelines.

Conclusion: In our cohort, the neuropathic pain severity was moderate and the frequency was lower than the literature. Although there are many guidelines, high proportion of patients were being treated by ineffective dosages or irrational treatments.

Keywords: Neuropathic pain, gabapentinoid, pregabalin, gabapentin, DN4, painDETECT

Cite this article as: Bekircan-Kurt CE, Inan B, Bulut O, Şengün I, Karli N, Gunes N, Çokal BG, Keskın Güler S, Yoldaş TK, Güner Ozcan Yüz D, Koç F, Ünlütürk Z, Erdoğan C, Uludağ B, Boz C, Tutuncu M, Akaln MA, Kamisli O, Ozcan A, Kahraman Koytak P, Uluç K, Erdem-Ozdamar S, Tan E. Neuropathic Pain Frequency in Neurology Outpatients: A Multicenter Study. Arch Neuropsychiatry 2021;58:257–260.

INTRODUCTION

Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibres (Aβ, Aδ and C fibres) and central neurons (1). Neuropathic pain is a major, generally persistent, epidemiological problem that may require lifelong treatment.

Diabetic polyneuropathy, postherpetic neuralgia, poststroke pain are common causes of neuropathic pain. Moreover, neuropathic pain may be a symptom of some neurological diseases such as Parkinson’s disease (2, 3). To date, several epidemiological studies have been established to estimate the prevalence of neuropathic pain. Cross-sectional studies done by postal or telephone interview survey, general practice research database conducted in general population or representative of general population showed that neuropathic pain prevalence varies between 0.8 and 17.9% (4–6). Considering these data, the prevalence of neuropathic pain has been estimated to be 7–10% in general population (3, 7). But, there is no epidemiological study about neuropathic pain in Turkish population, except one multicenter cross-sectional study which showed that the prevalence of neuropathic pain in Turkish patients with diabetic neuropathy is 14% (8). Thus, epidemiological studies are needed to determine diagnostic and therapeutic requirements. The aim of this
study is to evaluate the rate of neuropathic pain in neurology outpatient clinics by using valid and reliable pain scales and to review the treatments of patients with neuropathic pain.

**METHODS**

The study was conducted between 1^st^ September 2018 and 31^st^ December 2018 in eleven tertiary health care facilities in eight cities from different regions of Turkey. All outpatients were included in 5 centers whereas only outpatients with neuromuscular diseases were included in 5 and only multiple sclerosis (MS) outpatients were included in one center. All participants provided written informed consent to participate in this study and ethical approval was granted by the Hacettepe University Faculty of Medicine Ethical Review Board (GO 18/756). All patients were asked about neuropathic pain symptoms and their previous diagnosis were reviewed. Patients with previous neuropathic pain diagnosis or who have neuropathic pain symptoms were included to the study. Then, these patients were questioned by painDETECT (9) and douleur neuropathic en 4 questions (DN4) (10). Patients whose DN4 score is equal or higher than 4 and/or painDETECT score higher than 13 and/or patients previously diagnosed with neuropathic pain and who are on neuropathic pain treatment were considered patients with neuropathic pain. The neurological examination and the co-morbidities of these patients were recorded.

Statistical analyses were performed by using IBM SPSS (Statistical Package for Social Sciences) 22.0. There was great variability between the centers in terms of both total outpatient numbers and the number of patients with neuropathic pain. Thus, the rate of neuropathic pain in neurology patients was calculated by meta-analysis approach instead of equal or higher than 4 and/or painDETECT score higher than 13 and/or patients previously diagnosed with neuropathic pain and who are on neuropathic pain treatment were considered patients with neuropathic pain. The neurological examination and the co-morbidities of these patients were recorded.

The mean age of patients with neuropathic pain was 55.5±14.4 (18–98 years-old) and 57% of these patients were female. The mean duration of neuropathic pain was 24 months (mean 44.4±58.9 months; 10 days–480 months) and the diagnosis of neuropathic pain was made during the study in 19% of the patients for the first time. Abnormal neurological examination findings, such as decreased deep tendon reflexes and sensory loss, were observed in 60% of the patients. The most common cause of neuropathic pain was diabetic neuropathy seen in 39.2% (Figure 2), besides, 46% of patients with neuropathic pain had diabetes mellitus. Noteworthy, central neuropathic pain was relatively rare as present in 8% of the patients.

According to painDETECT, the mean overall pain intensity (during the last 4 weeks) was 5.7±2.4, whereas the mean pain intensity at the examination was 4.7±3.0. Additionally, 35% of the patients claimed that the most severe pain intensity was 10/10 during the last 4 weeks. Most of the patients (31.6%) described their pain as persistent with pain attacks and the pain radiates in 30.2%. The most common positive neuropathic pain symptom was tingling and prickling (87.9%) followed by burning (74.4%), electric shocks (62%), allodynia (46.6%), itching (35.2%) respectively. Furthermore, most of the patients (90.1%) also suffer from numbness in the painful area.

The mean DN4 questionnaire score was 6.1±2.1. While numbness was reported by most of the patients via painDETECT, hypoesthesia to contact

| Centers                                      | Outpatient Clinic Description | Total number of outpatients | Number of patients with NeuP | NeuP frequency |
|----------------------------------------------|-------------------------------|-----------------------------|------------------------------|----------------|
| Marmara University                           | Neuromuscular                 | 429                         | 81                           | 18.9%          |
| Dokuz Eylül University                      | General Neurology             | 3,406                       | 82                           | 2.4%           |
| Pamukkale University                        | General Neurology             | 1,931                       | 170                          | 8.8%           |
| Çukurova University                         | General Neurology             | 2,314                       | 111                          | 4.8%           |
| İnönü University                            | Neuromuscular                 | 620                         | 29                           | 4.7%           |
| Istanbul University Cerrahpaşa Medical Faculty | Neuromuscular               | 1,150                       | 44                           | 3.8%           |
| Ankara Training Hospital                    | Neuromuscular                 | 2,502                       | 42                           | 1.7%           |
| Hacettepe University                        | General Neurology             | 3,682                       | 46                           | 1.2%           |
| Uludağ University                           | General Neurology             | 3,203                       | 37                           | 1.2%           |
| Karadeniz Technical University              | Multiple sclerosis            | 1,757                       | 18                           | 1.0%           |
| Ege University                              | Neuromuscular                 | 1,853                       | 8                            | 0.4%           |
| Total                                       |                               | 22,847                      | 668                          | 2.7%           |

NeuP, neuropathic pain.
was observed in 68.7% and to pricking in 52.8% according to DN4. Although 46.6% of the patients described alldynia in painDETECT, pain provoked by brushing was detected in 28.1% of the patients.

478 patients (72.8%) were receiving pharmacological treatment for neuropathic pain (Table 2). The most common treatment was pregabalin monotherapy (59.2%), followed by gabapentin (15.1%). However, 70% of those receiving gabapentin and 46.7% of those receiving pregabalin were using ineffective doses. Moreover, 30 patients (4.6%) were on medications, such as a-lipoic acid, which are not in the neuropathic pain treatment guidelines.

Combination treatment was used in 15.9% of patients and the most common treatment combination was duloxetine with pregabalin. It is noteworthy that 6 patients (1.2%) were treated with pregabalin and gabapentin combination. Although painDETECT and DN4 scores did not differ between patients with and without treatment (p=0.978, p=0.368 respectively), the mean overall pain intensity (during the last 4 weeks) was lower in patients with treatment (p=0.027) according to painDETECT. Additionally, the frequency of highest pain intensity (10/10) was lower in patients with treatment (p=0.012).

DISCUSSION

Neuropathic pain is a well-known persistent pain syndrome with therapeutic challenge. The epidemiology of neuropathic pain has always been a hot topic for researchers. Moreover, adequate diagnostic tools and population data are important to determine therapeutic strategy and health care costs. The overall prevalence of neuropathic pain is estimated to be 7−10% (3, 7). This information comes from medical records, retrospective studies, cross-sectional studies done by postal or telephone-based survey (4−7, 11). As the diagnosis relies on patient-defined subjective assessments, it can be sometimes over or underdiagnosed. Although there are many scales and questionnaires, there is no ‘gold standard’ for determining whether or not an individual has neuropathic pain. DN4 (10), LANSS (12) and painDETECT (9) are the most commonly used screening tools in epidemiological studies. In this study we used two screening tools, DN4 and painDETECT, to increase reliability.

Previous prevalence studies of neuropathic pain in neurology patients consist of survey done among patients with distinct neurological conditions such as ischemic stroke (13) or multiple sclerosis (14). Moreover, our knowledge about the epidemiology of neuropathic pain in Turkey is limited to cross-sectional studies done in small number of patients (less than 1500 patients) with distinct diseases such as diabetes or low back pain (8, 15, 16). As might be expected, the frequency is high in patient with low back pain (43.9%) (15), rheumatic disorders (30%) (16) and diabetes (14%) (8). Interestingly, although we included neurology outpatients, the prevalence of neuropathic pain in our cohort was 2.7% that is lower than estimated neuropathic pain prevalence. This finding may be related to objective diagnostic criteria and the use of two diagnostic questionnaires. Moreover, the neuropathic pain intensity was generally moderate with a mean of 5.7±2.4 according to painDETECT and most of the patients suffer from persistent pain with pain attacks. The most common type of neuropathic pain was tingling and prickling seen in 87.9% followed by burning (74.4%). It is known that negative symptoms can accompany neuropathic pain. Noteworthy, the frequency of hypoesthesia was very high as 90.1% according to painDETECT, and most of the patients suffer from persistent pain with pain attacks. The causes of neuropathic pain.

Table 2. The neuropathic pain treatments

| Drug                                      | Number of patients (n) | Percentage (%) |
|-------------------------------------------|------------------------|----------------|
| Monotherapy                               | 402                    | 84.1           |
| Pregabalin                                 | 283                    | 59.2           |
| Gabapentin                                 | 72                     | 15.1           |
| Duloxetine                                 | 35                     | 7.3            |
| Carbamazepine                              | 4                      | 0.8            |
| Amitriptyline                              | 2                      | 0.4            |
| Fluoxetine                                 | 2                      | 0.4            |
| Escitalopram                               | 2                      | 0.4            |
| Sertraline                                 | 1                      | 0.25           |
| Lamotrigine                                | 1                      | 0.25           |
| Combination therapy                        | 76                     | 15.9           |
| Pregabalin + Duloxetine                    | 48                     | 10.0           |
| Gabapentin + Duloxetine                    | 5                      | 1.0            |
| Pregabalin + Carbamazepine                 | 5                      | 1.0            |
| Pregabalin + Amitriptyline                 | 4                      | 0.8            |
| Pregabalin + Gabapentin                    | 4                      | 0.8            |
| Carbamazepine + Amitriptyline             | 2                      | 0.4            |
| Pregabalin + Gabapentin + Duloxetine       | 2                      | 0.4            |
| Pregabalin + Amitriptyline + Duloxetine   | 1                      | 0.25           |
| Pregabalin + Amitriptyline + Carbamazepine | 1                      | 0.25           |
| Pregabalin + Fluoxetine                    | 1                      | 0.25           |
| Duloxetine + Fluoxetine                    | 1                      | 0.25           |
| Gabapentin + Sertraline                    | 1                      | 0.25           |
| Gabapentin + Amitriptyline                 | 1                      | 0.25           |
| Total                                      | 478                    | 100.0          |

In our cohort, not surprisingly, the most common cause of neuropathic pain was diabetic neuropathy and neuropathic pain prevalence was higher among patients with neuromuscular diseases than any other neurological conditions. Noteworthy, central neuropathic pain was relatively rare despite the cohort consisted of patients with all kinds of neurological disorders.
Another remarkable finding was that abnormal neurological findings were present only in 60% of patients with neuropathic pain. This underlines the necessity to use screening and diagnostic tools such as neuropathic pain questionnaires and quantitative sensory tests.

Most of the neuropathic pain treatments have moderate efficacy providing 50% of pain relief (17). In our cohort, the overall pain intensity was lower in patients with treatment but questionnaire scores did not differ between patients receiving and not receiving medical treatment. However, it is noteworthy that most of the patients, more than 70%, were not receiving effective dose of gabapentinoids. This finding could be related to the fear of abuse or side effects and the new limitation in prescription of these drugs in our country. Previous study of our group showed that the cost of irrational treatment on neuropathic pain accounted for 48% of all neuropathic pain treatment in 2007–2009 (18). Optimistically, the frequency of irrational treatment in our cohort was very low as 4.83%.

This study can represent the overall Turkish patients’ characteristics as it was conducted in 11 tertiary health care centers from different regions of Turkey. Besides, the outpatient services varied between the centers as some of them included patients all kinds of neurological diseases whereas some included patients with certain neurological conditions such as MS, neuromuscular diseases. However, the clinical and laboratory findings of the patients are limited due to high outpatient density in these centers and our findings are limited to neurology patients and to tertiary health care centers. Thus, longitudinal studies with a sample which is representing general population and identifying risk and causal factors are still needed.

Acknowledgement: The authors thank the doctors who took part in the follow-up of these patients.

Ethics Committee Approval: Ethical approval was granted by the Hacettepe University Faculty of Medicine Ethical Review Board (GO 18/756).

Informed Consent: All participants provided written informed consent to participate in this study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept- CEBK, ET, Design- CEBK, ET, SEO, Supervision- CEBK, ET, Resource- CEBK, ET, Materials- CEBK, BI, OB, IŞ, NK, NG, BGC, SKG, TKY, DGO, FK, ZU, CE, BU, CB, MT, MAA, ÝK, AO, PKK, KU, SEO, ET, Data Collection and/or Processing- CEBK, BI, OB, IŞ, NK, NG, BGC, SKG, TKY, DGO, FK, ZU, CE, BU, CB, MT, MAA, ÝK, AO, PKK, KU, SEO, ET, Analysis and/or Interpretation- CEBK, BI, ET, SEO, Literature Search- CEBK, BI, Writing- CEBK, BI, ET, SEO, Critical Reviews- CEBK, BI, ET, SEO.

Conflict of Interest: None.

Financial Disclosure: Study funded by Abdi Ibrahim Ilac Sanayi ve Tic. A.S. The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

REFERENCES
1. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmkko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630–1635. [Crossref]
2. Moreno CB, Hernandez-Beltran N, Munevar D, Gutierrez-Alvarez AM. Central neuropathic pain in Parkinson’s disease. Neurologia 2012;27:500–503. [Crossref]
3. Colloca L, Ludman T, Bouahassira D, Baron R, Dickinson AH, Yarnitsky D, Freeman R, Truini A, Attal N, Finnerup NB, Eccleston C, Kalso E, Bennett DL, Dworkin RH, Raja SN. Neuropathic pain. Nat Rev Dis Primers 2017;3:17002. [Crossref]
4. Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136:380–387. [Crossref]
5. Dieleman JP, Kerklaan J, Huygen FJ, Bouna PA, Sturkenboom MC. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 2008;137:681–688. [Crossref]
6. Toth C, Landers J, Wiebe S. The prevalence and impact of chronic pain with neuropathic pain symptoms in the general population. Pain Med 2009;10:918–929. [Crossref]
7. Smith BH. Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep 2012;16:191–198. [Crossref]
8. Erbas T, Ertas M, Yucel A, Keskinaslan A, Senocak M; TURENP Study Group. Prevalence of peripheral neuropathy and painful peripheral neuropathy in Turkish diabetic patients. J Clin Neurophysiol 2011;28:51–55. [Crossref]
9. Alkan H, Ardic F, Erdogan C, Sahin F, Sarsan A, Findikoglu G. Turkish version of the painDETECT questionnaire in the assessment of neuropathic pain: a validity and reliability study. Pain Med 2013;14:1933–1943. [Crossref]
10. Unal-Cevik I, Sarioglu-Ay S, Evick D. A comparison of the DN4 and LANSS questionnaires in the assessment of neuropathic pain: validity and reliability of the Turkish version of DN4. J Pain 2010;11:1129–1135. [Crossref]
11. Van Den Kerkhof EG, Mann EG, Torrance N, Smith BH, Johnson A, Gilron I. An Epidemiological Study of Neuropathic Pain Symptoms in Canadian Adults. Pain Res Manag 2016;2016:9815750. [Crossref]
12. Koc R, Erdemoglu AK. Validity and reliability of the Turkish Self-administered Leeds Assessment of Neuropathic Pain and Signs (S-LANSS) questionnaire. Pain Med 2010;11:1107–1114. [Crossref]
13. Aprile I, Briani C, Pazzaglia C, Cecchi F, Negrini S, Padua L; Don Carlo Gnocchi Pain-Rehab Group. Pain in stroke patients: characteristics and impact on the rehabilitation treatment. A multicenter cross-sectional study. Eur J Phys Rehabil Med 2015;51:725–736. [Crossref]
14. Truini A, Barbanti P, Pozzilli C, Cruccu G. A mechanism-based classification of pain in multiple sclerosis. J Neurol 2013;260:351–367. [Crossref]
15. Erhan B, Gumusu K, Kara B, Bulut GT, Yalcinkaya EY. The frequency of neuropathic pain in Turkish patients with low back pain: a cross-sectional study. Acta Neurol Belg 2020. [Crossref]
16. Garip Y, Eser F, Kilicarslan A, Bodur H. Prevalence of Neuropathic Pain in Rheumatic Disorders: Association With Disease Activity, Functional Status and Quality of Life. Arch Rheumatol 2015;30:231–237. [Crossref]
17. Finnerup NB, Attal N, Haroutounian S, Mcnicol E, Baron R, Dworkin RH, Gilron I, Haanpaa M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162–173. [Crossref]
18. Tan E, Akinci A, Ayvaz G, Erbaş T, Erbaş M, Güç O, Hegpüler S, Kiraz S, Oçaş S, Öztürk Ş, Özyalın N, Palaoğlu S, Uyar M, Unal S, Yalçın Ş. Irrational drug use in neuropathic pain treatment: a two-year data analysis. Int J Med Biomed Res 2013;2:202–206. [Crossref]